Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 4/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | TLR4 | O00206 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL605486 | 0.99 | ALDH1A1 (0.68) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL2520795 | 0.95 | EPHX1 (0.64) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL4072126 | 0.95 | EPHX1 (0.64) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL2522491 | 0.95 | EPHX1 (0.64) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL240038 | 0.92 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL2901586 | 0.92 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL240039 | 0.92 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| Hydrochloric Acid SCHEMBL2854037 | 0.90 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1CTSL | |
| Hydrochloric Acid SCHEMBL243634 | 0.90 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1CTSL | |
| Hydrochloric Acid SCHEMBL243635 | 0.90 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | claimed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4658658-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-6506749-B2 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2003-01-14 | — | — | US | disclosed |
| US-6476054-B1 | Cyclic amine modulators of chemokine receptor activity | MERCK & CO., INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2002-09-26 | — | — | US | disclosed |
| WO-2002064594-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002018380-A1 | 7-OXO PYRIDOPYRIMIDINES AS INHIBITORS OF A CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| US-6140349-A | FOR PROPHYLAXIS AND THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) INFECTIONS AND ACQUIRED IMMUNODEDICIENCY SYNDROME | MERCK & CO., INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-4864023-A | MICROBIOCIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4801584-A | ANTIMICROBIAL | HOFFMANN-LA ROCHE INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0262318-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-04-06 | — | — | EP | disclosed |
| EP-0259804-A2 | Pyrido[3,2,1-ij]-1,3,4-benzoxadiazine derivatives, process for their preparation, resulting pharmaceutical preparations and intermediates for use in the process | F. HOFFMANN-LA ROCHE AG (CH) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | PSMB2, PSMB7, MDM2 | ALDH1A1 3471/4885GAA 2501/4885TSHR 1167/4885 |
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDK6, CDKL1, CDK3 | ALDH1A1 2581/4885GAA 4121/4885TSHR 887/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | ALDH1A1 3269/4885GAA 1694/4885TSHR 588/4885 |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | MAPK1, MAP3K1, CDK1 | ALDH1A1 2856/4885GAA 4533/4885TSHR 2092/4885 |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | CDK2, SKP2, CCNK | ALDH1A1 3087/4885GAA 1022/4885TSHR 4070/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | ALDH1A1 3100/4885GAA 4882/4885TSHR 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.